Works matching AU Jing, Hongmei


Results: 107
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study.

    Published in:
    Journal of Hematology & Oncology, 2024, v. 17, n. 1, p. 1, doi. 10.1186/s13045-024-01646-2
    By:
    • Yang, Jianliang;
    • Song, Yongping;
    • Zhou, Keshu;
    • Li, Zhiming;
    • Zhang, Mingzhi;
    • Jing, Hongmei;
    • Wang, Zhen;
    • Yu, Li;
    • Meng, Wei;
    • Lu, Qiying;
    • Tian, Wenzhi;
    • Shi, Yuankai
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22

    Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.

    Published in:
    Annals of Hematology, 2024, v. 103, n. 10, p. 4183, doi. 10.1007/s00277-024-05823-8
    By:
    • Zhou, Keshu;
    • Wang, Tingyu;
    • Pan, Ling;
    • Xu, Wei;
    • Jin, Jie;
    • Zhang, Wei;
    • Hu, Yu;
    • Hu, Jianda;
    • Feng, Ru;
    • Li, Ping;
    • Liu, Zhougang;
    • Liu, Peng;
    • Jing, Hongmei;
    • Gao, Sujun;
    • Zhang, Huilai;
    • Yu, Kang;
    • Wang, Zhao;
    • Zhu, Xiongpeng;
    • Sun, Zimin;
    • Li, Fei
    Publication type:
    Article
    23
    24
    25

    Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.

    Published in:
    Annals of Hematology, 2024, v. 103, n. 3, p. 855, doi. 10.1007/s00277-023-05558-y
    By:
    • Zhou, Huixing;
    • Wang, Yafei;
    • Chen, Jiao;
    • He, Aili;
    • Jin, Jie;
    • Lu, Quanyi;
    • Zhao, Ying;
    • Li, Junjun;
    • Hou, Ming;
    • Su, Liping;
    • Lai, Xun;
    • Wang, Wei;
    • Liu, Lihong;
    • Ma, Yanping;
    • Gao, Da;
    • Lai, Wenhong;
    • Zhou, Xin;
    • Jing, Hongmei;
    • Zhang, Jinqiao;
    • Yang, Wei
    Publication type:
    Article
    26
    27
    28
    29
    30

    2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.

    Published in:
    Cancer Biology & Medicine, 2023, v. 20, n. 2, p. 129, doi. 10.20892/j.issn.2095-3941.2022.0585
    By:
    • Ping Li;
    • Yang Liu;
    • Yun Liang;
    • Jian Bo;
    • Sujun Gao;
    • Yongxian Hu;
    • Yu Hu;
    • He Huang;
    • Xiaojun Huang;
    • Hongmei Jing;
    • Xiaoyan Ke;
    • Jianyong Li;
    • Yuhua Li;
    • Qifa Liu;
    • Peihua Lu;
    • Heng Mei;
    • Ting Niu;
    • Yongping Song;
    • Yuqin Song;
    • Liping Su
    Publication type:
    Article
    31
    32

    The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study.

    Published in:
    Cancer Biology & Medicine, 2021, v. 18, n. 3, p. 841, doi. 10.20892/j.issn.2095-3941.2020.0413
    By:
    • Wei Zhang;
    • Liping Su;
    • Lihong Liu;
    • Yuhuan Gao;
    • Quanshun Wang;
    • Hang Su;
    • Yuhuan Song;
    • Huilai Zhang;
    • Jing Shen;
    • Hongmei Jing;
    • Shuye Wang;
    • Xinan Cen;
    • Hui Liu;
    • Aichun Liu;
    • Zengjun Li;
    • Jianmin Luo;
    • Jianxia He;
    • Jingwen Wang;
    • O'Connor, O. A.;
    • Daobin Zhou
    Publication type:
    Article
    33

    P-211: Phase 2 MARCH study: ATG-010 plus Dexamethasone in Chinese relapsed/refractory Multiple Myeloma (RRMM) patients previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S155, doi. 10.1016/S2152-2650(21)02338-7
    By:
    • Lugui Qiu;
    • Weijun Fu;
    • Chengcheng Fu;
    • Wenming Chen;
    • Chunkang Chang;
    • Baijun Fang;
    • Gang An;
    • Yongqiang Wei;
    • Zhen Cai;
    • Sujun Gao;
    • Jianyu Weng;
    • Lijun Chen;
    • Hongmei Jing;
    • Fei Li;
    • Zhuogang Liu;
    • Xiequn Chen;
    • Jing Liu;
    • Ling Li;
    • Yang Yu;
    • Aihua Wang
    Publication type:
    Article
    34

    P-160: Efficacy and safety of induction therapy with IAd versus IRd regimen in fragile elderly patients with newly diagnosed multiple myeloma: results of a prospective multicenter clinical trail.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S123, doi. 10.1016/S2152-2650(21)02287-4
    By:
    • Li Bao;
    • Minqiu Lu;
    • Peng Liu;
    • Junling Zhuang;
    • Mei Zhang;
    • Zhongjun Xia;
    • Zhenling Li;
    • Hongmei Jing;
    • Yin Wu;
    • Wen ming Chen;
    • Hebing Zhou;
    • Yuping Gong;
    • Rong Fu;
    • Zhenyu Yan;
    • Wenrong Huang;
    • Bin Chu;
    • Yutong Wang;
    • Yongqing Zhang
    Publication type:
    Article
    35

    P-142: Ixazomib versus Lenalidomide or Ixazomib and Lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S113, doi. 10.1016/S2152-2650(21)02269-2
    By:
    • Zhe Zhuang;
    • Hong Yu;
    • Qinhua Liu;
    • Dongmei Zou;
    • Lei Shi;
    • Ying Tian;
    • Fei Dong;
    • Yanping Ma;
    • Wei-wei Tian;
    • Ru Feng;
    • Shuangjiao Liu;
    • Hui Liu;
    • Liang-Ming Ma;
    • Hongmei Jing;
    • Wenming Chen;
    • Yin Wu;
    • Li Bao;
    • Wanling Sun;
    • Rong Fu;
    • Junling Zhuang
    Publication type:
    Article
    36

    P-141: Lenalidomide versus Thalidomide or Bortezomib as maintenance regimen for non-transplant patients with multiple myeloma: multi-center real world experiences in China.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S112, doi. 10.1016/S2152-2650(21)02268-0
    By:
    • Zhe Zhuang;
    • Lei Shi;
    • Ying Tian;
    • Dongmei Zou;
    • Ru Feng;
    • Fei Dong;
    • Yanping Ma;
    • Hong Yu;
    • Wei-wei Tian;
    • Shuangjiao Liu;
    • Liang-Ming Ma;
    • Rong Fu;
    • Hongmei Jing;
    • Hui Liu;
    • Wanling Sun;
    • Wenming Chen;
    • Yin Wu;
    • Li Bao;
    • Junling Zhuang
    Publication type:
    Article
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46

    Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multicentered study in China.

    Published in:
    Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1028571
    By:
    • Zhe Zhuang;
    • Ying Tian;
    • Lei Shi;
    • Dongmei Zou;
    • Ru Feng;
    • Wei-wei Tian;
    • Hong Yu;
    • Fei Dong;
    • Aijun Liao;
    • Yanping Ma;
    • Qinhua Liu;
    • Shuangjiao Liu;
    • Hongmei Jing;
    • Rong Fu;
    • Liang-ming Ma;
    • Hui Liu;
    • Wanling Sun;
    • Li Bao;
    • Yin Wu;
    • Wenming Chen
    Publication type:
    Article
    47
    48
    49
    50